Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1136/rmdopen-2015-000213 http://scihub22266oqcxt.onion/10.1136/rmdopen-2015-000213 C4874056!4874056!27252893     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       RMD+Open 2016 ; 2 (1): ä Nephropedia Template TP {{tp|p=27252893|t=2016. Malignancy rates in patients with rheumatoid arthritis treated with tocilizumab |pdf=|usr=}}{{27252893}} gab.com Text Malignancy rates in patients with rheumatoid arthritis treated with tocilizumab JO: RMD Open http://www.kidney.de/pget.php?&tw=1&pmid=27252893 #FOAvip Objective: To analyse malignancy rates in patients with rheumatoid arthritis (RA) treated with tocilizumab. Methods: Patients who received tocilizumab or placebo+methotrexate/disease-modifying antirheumatic drugs in the double-blind phases of 5-phase three trials or who received at least 1 dose of tocilizumab in the long-term extension studies were analysed up to the 2 May 2012 cut-off date. Malignancies were monitored throughout the studies, analysed and adjudicated as malignant by medical review. Risk was compared with that in the general population using standardised incidence ratios (SIRs) based on data from the Surveillance Epidemiology and End Results SEER (US general population) and GLOBOCAN (non-US general population) databases. Results: In total, 4009 patients in the tocilizumab all-exposure population were included. Mean treatment duration was 4.0?years (mean 5.1 (range 0.0?6.8); total observation time was 16?120.1 patient-years (PY). The adjudicated malignancy rate (95% CI) was 1.26/100 PY (1.09 to 1.44) and remained constant over time. The SIR (95% CI) for all malignancies combined, excluding non-melanoma skin cancer, was 1.36 (1.01 to 1.80) for US and 1.81 (1.44 to 2.23) for non-US populations, driven primarily by higher rates in lung and bronchus (US/non-US) malignancies and prostate cancer and non-Hodgkin lymphoma (non-US), in contrast to those for the general populations; these higher rates are in line with those expected in patients with RA or in the geographic regions studied. Conclusions: Malignancy rates remained stable with long-term tocilizumab treatment, and malignancy types and rates were consistent with those expected in patients with RA. Twit Text FOAVip Malignancy rates in patients with rheumatoid arthritis treated with tocilizumab ????RMD Open http://www.kidney.de/pget.php?&tw=1&pmid=27252893 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27252893 #FOAvip English Wikipedia <ref>{{Cite pmid|27252893}}</ref> Malignancy rates in patients with rheumatoid arthritis treated with tocilizumab #MMPMID27252893 Rubbert-Roth A; Sebba A; Brockwell L; Kelman A; Porter-Brown B; Pulley J; Napalkov P; van Vollenhoven RF RMD Open 2016[]; 2 (1): ä PMID27252893show ga Objective: To analyse malignancy rates in patients with rheumatoid arthritis (RA) treated with tocilizumab. Methods: Patients who received tocilizumab or placebo+methotrexate/disease-modifying antirheumatic drugs in the double-blind phases of 5-phase three trials or who received at least 1 dose of tocilizumab in the long-term extension studies were analysed up to the 2 May 2012 cut-off date. Malignancies were monitored throughout the studies, analysed and adjudicated as malignant by medical review. Risk was compared with that in the general population using standardised incidence ratios (SIRs) based on data from the Surveillance Epidemiology and End Results SEER (US general population) and GLOBOCAN (non-US general population) databases. Results: In total, 4009 patients in the tocilizumab all-exposure population were included. Mean treatment duration was 4.0?years (mean 5.1 (range 0.0?6.8); total observation time was 16?120.1 patient-years (PY). The adjudicated malignancy rate (95% CI) was 1.26/100 PY (1.09 to 1.44) and remained constant over time. The SIR (95% CI) for all malignancies combined, excluding non-melanoma skin cancer, was 1.36 (1.01 to 1.80) for US and 1.81 (1.44 to 2.23) for non-US populations, driven primarily by higher rates in lung and bronchus (US/non-US) malignancies and prostate cancer and non-Hodgkin lymphoma (non-US), in contrast to those for the general populations; these higher rates are in line with those expected in patients with RA or in the geographic regions studied. Conclusions: Malignancy rates remained stable with long-term tocilizumab treatment, and malignancy types and rates were consistent with those expected in patients with RA. äMalignancy rates in patients with rheumatoid arthritis treated with to(epmc).pdf DeepDyve Pubget Overpricing